Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - SR5
SR5 Details
Status: Closed 
Activation Date: 2007JUL03
Closing Date: 2010MAY11
Phase: III 

Description: Randomized Trial of Single Agent Doxorubicin Vs. Doxorubicin plus Ifosfamide in First Line Treatment of Advanced or Metastatic Soft Tissue Sarcoma 

Eligibility: Patients with advanced or metastatic soft tissue sarcoma (FNLCC grades 2-3) with RECIST measurable lesions and at least 6 months since adjuvant chemotherapy and PS < 1 (WHO). 

Objective: Overall survival; Response, toxicity and treatment related mortality. 

Participation: Open to member centres 

Lay Description: The objective is to determine whether intensive combination chemotherapy with ifosfamide and doxorubicin is superior to doxorubicin alone in terms of overall survival. 

Primary Publication Show

Other Publications Show

Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
SARCOMA SR5 13 9 10 10
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
SARCOMA SR5 13 0 0
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
SARCOMA SR5 13 0 0 0 0 0 0 0 0